2.57
+0.11(+4.47%)
Currency In USD
| Previous Close | 2.46 |
| Open | 2.44 |
| Day High | 2.59 |
| Day Low | 2.41 |
| 52-Week High | 7.13 |
| 52-Week Low | 0.46 |
| Volume | 1.32M |
| Average Volume | 2M |
| Market Cap | 723.22M |
| PE | -4.67 |
| EPS | -0.55 |
| Moving Average 50 Days | 2.74 |
| Moving Average 200 Days | 1.87 |
| Change | 0.11 |
If you invested $1000 in ProKidney Corp. (PROK) since IPO date, it would be worth $250.25 as of December 04, 2025 at a share price of $2.53. Whereas If you bought $1000 worth of ProKidney Corp. (PROK) shares 3 years ago, it would be worth $241.41 as of December 04, 2025 at a share price of $2.53.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025
GlobeNewswire Inc.
Nov 06, 2025 4:00 PM GMT
In patients with advanced chronic kidney disease (CKD) and diabetes, treatment with rilparencel resulted in statistically significant and clinically meaningful slowing of CKD progressionBilateral kidney injection with rilparencel resulted in a 4.6 mL
ProKidney to Participate in Two Upcoming Conferences: Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference
GlobeNewswire Inc.
Oct 29, 2025 11:30 AM GMT
WINSTON-SALEM, N.C., Oct. 29, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that senior m
ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2025
GlobeNewswire Inc.
Oct 20, 2025 11:30 AM GMT
WINSTON-SALEM, N.C., Oct. 20, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that the Comp